Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
about
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 TrialClinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.Predictors of sudden cardiac death in atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
P2860
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@en
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@nl
type
label
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@en
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@nl
prefLabel
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@en
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@nl
P2093
P2860
P50
P356
P1476
Sudden Cardiac Death in Patien ...... m the ENGAGE AF-TIMI 48 Trial.
@en
P2093
Alon Eisen
Anthony Dalby
Christian T Ruff
Francesco Nordio
Howard Rutman
Maria Dorobantu
Michele Mercuri
Ramón Corbalán
Stephen D Wiviott
P2860
P356
10.1161/JAHA.116.003735
P577
2016-07-08T00:00:00Z